Lasmiditan for the Acute Treatment of Migraine

References

• Burch RC , BuseDC , LiptonRB. Migraine: epidemiology, burden, and comorbidity. Neurol. Clin.37(4), 631–649 (2019).
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders (3rd edition). Cephalalgia38(1), 1–211 (2018).
   PubMed Web of Science ®Google Scholar
• Collaborators G . Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet392(10159), 1789–1858 (2018).
   PubMed Web of Science ®Google Scholar
• Edmeads J , MackellJA. The economic impact of migraine: an analysis of direct and indirect costs. Headache42(6), 501–509 (2002).
   PubMed Web of Science ®Google Scholar
• Hawkins K , WangS , RupnowM. Direct cost burden among insured US employees with migraine. Headache48(4), 553–563 (2008).
   PubMed Web of Science ®Google Scholar
• Lipton RB , BuseDC , SerranoD , HollandS , ReedML. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache53(8), 1300–1311 (2013).
   PubMed Web of Science ®Google Scholar
• Jacobs B , DussorG. Neurovascular contributions to migraine: moving beyond vasodilation. Neuroscience338, 130–144 (2016).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ , HollandPR , Martins-OliveiraM , HoffmannJ , SchankinC , AkermanS. Pathophysiology of migraine: a disorder of sensory processing. Physiol. Rev.97(2), 553–622 (2017).
   PubMed Web of Science ®Google Scholar
• Koehler PJ , Tfelt-HansenPC. History of methysergide in migraine. Cephalalgia28(11), 1126–1135 (2008).
   PubMed Web of Science ®Google Scholar
• Sicuteri FTA , AnselmiB. Biochemical investigations in headache: increase in hydroxyindolacetic acid excretion during migraine attacks. Int. Arch. Allergy19, 55–58 (1961).
   Web of Science ®Google Scholar
• Giamberardino MA , MartellettiP. Emerging drugs for migraine treatment. Expert Opin. Emerg Drugs20(1), 137–147 (2015).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ , WietechaLA , DennehyEBet al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain142(7), 1894–1904 (2019).
   PubMed Web of Science ®Google Scholar
• Ferrari MD , RoonKI , LiptonRB , GoadsbyPJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet358(9294), 1668–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Marmura MJ , SilbersteinSD , SchwedtTJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache55(1), 3–20 (2015).
   PubMed Web of Science ®Google Scholar
• Levy D , Labastida-RamirezA , MaassenvandenbrinkA. Current understanding of meningeal and cerebral vascular function underlying migraine headache. Cephalalgia39(13), 1606–1622 (2019).
   PubMed Web of Science ®Google Scholar
• Olesen J , BursteinR , AshinaM , Tfelt-HansenP. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol.8(7), 679–690 (2009).
   PubMed Web of Science ®Google Scholar
• Messlinger K . Migraine: where and how does the pain originate?Exp. Brain Res.196(1), 179–193 (2009).
   PubMed Web of Science ®Google Scholar
• Levy D , KainzV , BursteinR , StrassmanAM. Mast cell degranulation distinctly activates trigemino-cervical and lumbosacral pain pathways and elicits widespread tactile pain hypersensitivity. Brain Behav. Immun.26(2), 311–317 (2012).
   PubMed Web of Science ®Google Scholar
• Noseda R , BursteinR. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain. Pain154(Suppl. 1), 2013).
   Google Scholar
• Rubio-Beltrán E , Labastida-RamírezA , VillalónCM , MaassenvandenbrinkA. Is selective 5-HT receptor agonism an entity apart from that of the triptans in antimigraine therapy?Pharmacol. Ther.186, 88–97 (2018).
   PubMed Web of Science ®Google Scholar
• Macgregor EA . Migraine. Ann. Intern. Med.166(7), ITC49–ITC64 (2017).
   PubMedGoogle Scholar
• Mathew PG , KleinBC. Getting to the heart of the matter: migraine, triptans, DHE, ditans, CGRP antibodies, first/second-generation gepants, and cardiovascular risk. Headache: The Journal of Head and Face Pain59(8), 1421–1426 (2019).
   PubMed Web of Science ®Google Scholar
• Cameron C , KellyS , HsiehSCet al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache55(Suppl. 4), 221–235 (2015).
   PubMed Web of Science ®Google Scholar
• Nelson DL , PhebusLA , JohnsonKWet al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia30(10), 1159–1169 (2010).
   PubMed Web of Science ®Google Scholar
• Curto M , CipollaF , CisaleGYet al. Profiling lasmiditan as a treatment option for migraine. Expert Opin. Pharmacother.21(2), 147–153 (2020).
   PubMed Web of Science ®Google Scholar
• Capi M , DeAndrés F , LionettoLet al. Lasmiditan for the treatment of migraine. Expert Opin. Investig. Drugs26(2), 227–234 (2017).
   PubMed Web of Science ®Google Scholar
• Negro A , KoverechA , MartellettiP. Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. J. Pain Res.11, 515–526 (2018).
   PubMed Web of Science ®Google Scholar
• Rubio-Beltrán E , Labastida-RamírezA , HaanesKAet al. Characterization of binding, functional activity, and contractile responses of the selective 5-HT. Br. J. Pharmacol.176(24), 4681–4695 (2019).
   PubMed Web of Science ®Google Scholar
• REYVOW (lasmiditan). (2019).
   Google Scholar
• PubChem Compound Summary for CID 11610526, Lasmiditan. (2006).
   Google Scholar
• Labastida-Ramírez A , Rubio-BeltránE , HaanesKAet al. Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system. Pain161(5), 1092–1099 (2020).
   PubMed Web of Science ®Google Scholar
• Hendrikse ER , BowerRL , HayDL , WalkerCS. Molecular studies of CGRP and the CGRP family of peptides in the central nervous system. Cephalalgia39(3), 403–419 (2019).
   PubMed Web of Science ®Google Scholar
• Lassen LH , HaderslevPA , JacobsenVB , IversenHK , SperlingB , OlesenJ. CGRP may play a causative role in migraine. Cephalalgia22(1), 54–61 (2002).
   PubMed Web of Science ®Google Scholar
• Cernuda-Morollón E , LarrosaD , RamónC , VegaJ , Martínez-CamblorP , PascualJ. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology81(14), 1191–1196 (2013).
   PubMed Web of Science ®Google Scholar
• Ashina M , BendtsenL , JensenR , SchifterS , OlesenJ. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain86(1-2), 133–138 (2000).
   PubMed Web of Science ®Google Scholar
• Oswald JC , SchusterNM. Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice. J. Pain Res.11, 2221–2227 (2018).
   PubMed Web of Science ®Google Scholar
• Mecklenburg J , RaffaelliB , NeebL , SanchezDel Rio M , ReuterU. The potential of lasmiditan in migraine. Ther. Adv. Neurol.Disord.13, 1756286420967847 (2020).
   Web of Science ®Google Scholar
• Tsai M , CaseM , ArdayfioP , HochstetlerH , WilbrahamD. Effects of lasmiditan on cardiovascular parameters and pharmacokinetics in healthy subjects receiving oral doses of propranolol. Clin. Pharmacol. Drug Dev.9(5), 629–638 (2020).
   PubMed Web of Science ®Google Scholar
• Wilbraham D , BergPH , TsaiMet al. Abuse potential of lasmiditan: a Phase 1 randomized, placebo- and alprazolam-controlled crossover study. J. Clin. Pharmacol.60(4), 495–504 (2020).
   PubMed Web of Science ®Google Scholar
• Kudrow D , KregeJH , HundemerHPet al. Issues impacting adverse event frequency and severity: differences between randomized Phase 2 and Phase 3 clinical trials for lasmiditan. Headache60(3), 576–588 (2020).
   PubMed Web of Science ®Google Scholar
• Kuca B , SilbersteinSD , WietechaLet al. Lasmiditan is an effective acute treatment for migraine: a Phase 3 randomized study. Neurology91(24), e2222–e2232 (2018).
   PubMed Web of Science ®Google Scholar
• Ashina M , VasudevaR , JinLet al. Onset of efficacy following oral treatment with lasmiditan for the acute treatment of migraine: integrated results from 2 randomized double-blind placebo-controlled Phase 3 Clinical Studies. Headache59(10), 1788–1801 (2019).
   PubMed Web of Science ®Google Scholar
• Raffaelli B , IsraelH , NeebL , ReuterU. The safety and efficacy of the 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine. Expert Opin. Pharmacother.18(13), 1409–1415 (2017).
   PubMed Web of Science ®Google Scholar
• Brandes JL , KliseS , KregeJHet al. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia39(11), 1343–1357 (2019).
   PubMed Web of Science ®Google Scholar
• Brandes JL , KliseS , KregeJHet al. Long-term safety and efficacy of lasmiditan for acute treatment of migraine: final results of the GLADIATOR study. Cephalalgia Reports3, 2515816320958176 (2020).
   Google Scholar
• Smith T , KregeJH , RathmannSSet al. Improvement in function after lasmiditan treatment: post hoc analysis of data from Phase 3 studies. Neurol. Ther.9(2), 459–471 (2020).
   PubMed Web of Science ®Google Scholar
• Lipton RB , LombardL , RuffDDet al. Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study. J. Headache Pain21(1), 20 (2020).
   PubMed Web of Science ®Google Scholar
• Ashina M , ReuterU , SmithTet al. Randomized, controlled trial of lasmiditan over four migraine attacks: findings from the CENTURION study. Cephalalgia41(3), 294–304 (2021).
   PubMed Web of Science ®Google Scholar
• REYVOW (lasmiditan) C-V demonstrated pain freedom from migraine attacks at 60 minutes and up to 48 hours in new Phase 3 Study. REYVOW showed significant therapeutic gains of 17–21% for pain freedom at 2 hours and met all 18 gated endpoints (2020).
   Google Scholar
• Yang Y , SunY , GaoB , WangZ , ChenZ , WangZ. Lasmiditan for acute treatment of migraine in adults: a systematic review and meta-analysis of randomized controlled trials. CNS Drugs34(10), 1015–1024 (2020).
   PubMed Web of Science ®Google Scholar
• Zhu H , TangY , ZhouT , SongJ. The efficacy of lasmiditan for the treatment of migraine: a meta-analysis of randomized controlled studies. Clin. Neuropharmacol.43(6), 191–195 (2020).
   PubMed Web of Science ®Google Scholar
• Hou M , XingH , LiCet al. Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis. The Journal of Headache and Pain21(1), 66 (2020).
   PubMed Web of Science ®Google Scholar
• Krege JH , RizzoliPB , LiffickEet al. Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: results from SAMURAI and SPARTAN. Cephalalgia39(8), 957–966 (2019).
   PubMed Web of Science ®Google Scholar
• Lamb YN . Lasmiditan: First Approval. Drugs79(18), 1989–1996 (2019).
   PubMed Web of Science ®Google Scholar
• Tepper SJ , KregeJH , LombardLet al. Characterization of dizziness after lasmiditan usage: findings from the SAMURAI and SPARTAN acute migraine treatment randomized trials. Headache59(7), 1052–1062 (2019).
   PubMed Web of Science ®Google Scholar
• Loo LS , AilaniJ , SchimJet al. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. J. Headache Pain20(1), 84 (2019).
   PubMedGoogle Scholar
• Doty EG , KregeJH , JinL , RaskinJ , HalkerSingh RB , KalidasK. Sustained responses to lasmiditan: results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine. Cephalalgia39(12), 1569–1576 (2019).
   PubMed Web of Science ®Google Scholar
• Loo LS , PlatoBM , TurnerIMet al. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the Phase 3 trials (SAMURAI and SPARTAN). BMC Neurol.19(1), 191 (2019).
   PubMed Web of Science ®Google Scholar
• Clemow DB , BayganiSK , HauckPM , HultmanCB. Lasmiditan in patients with common migraine comorbidities: a post hoc efficacy and safety analysis of two Phase 3 randomized clinical trials. Curr. Med. Res. Opin.36(11), 1791–1806 (2020).
   PubMed Web of Science ®Google Scholar
• Shapiro RE , HochstetlerHM , DennehyEBet al. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, Phase 3 trials. J. Headache Pain20(1), 90 (2019).
   PubMed Web of Science ®Google Scholar
• Vargas BB , MagisD , DotyEet al. Assessment to identify predictors of 2-hour pain freedom among patients enrolled in 2 Phase 3 studies of lasmiditan for acute treatment of migraine (1763). Neurology94(Suppl. 15), 1763 (2020).
   Web of Science ®Google Scholar
• Knievel K , BuchananAS , LombardLet al. Lasmiditan for the acute treatment of migraine: subgroup analyses by prior response to triptans. Cephalalgia40(1), 19–27 (2020).
   PubMed Web of Science ®Google Scholar
• Franklin M , DruytsE. ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine. J. Manag. Care Spec. Pharm.26(11), 1464–1466 (2020).
   PubMed Web of Science ®Google Scholar
• Doty EG , KregeJH , PohlG , CaseM , DowsettSA , TepperSJ. Pain freedom at 2 to 8 hours with lasmiditan: a comparison with rimegepant and ubrogepant. Headache60(8), 1793–1796 (2020).
   PubMed Web of Science ®Google Scholar
• Johnston K , PopoffE , DeightonAet al. Comparative efficacy and safety of rimegepant versus ubrogepant and lasmiditan for acute treatment of migraine: a Network Meta-Analysis (NMA) (4369). Neurology94(Suppl. 15), 4369 (2020).
   Web of Science ®Google Scholar
• Pearlman EM , WilbrahamD , DennehyEBet al. Effects of lasmiditan on simulated driving performance: results of two randomized, blinded, crossover studies with placebo and active controls. Hum. Psychopharmacol.35(5), e2732 (2020).
   PubMed Web of Science ®Google Scholar
• Dodick D , MartinV. Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Cephalalgia24(6), 417–424 (2004).
   PubMed Web of Science ®Google Scholar